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Moral imperialism is expressed in attempts to 
impose moral standards from one particular 
culture, geopolitical region or culture onto other 
cultures, regions or countries. Examples of Direct 
Moral Imperialism can be seen in various recur-
rent events involving multi-centric clinical tri-
als promoted by developed (central) countries in 
poor and developing (peripheral) countries, par-
ticularly projects related to the theory of double 
standards in research. After the WMA General 
Assembly refused to change the Helsinki Declara-
tion – which would have given moral recognition 
to the above mentioned theory – the USA aban-
doned the declaration and began to promote re-
gional seminars in peripheral countries with the 
aim of “training” researchers on ethical perspec-
tives that reflect America’s best interests. Individ-
uals who received such training became trans-
mitters of these central countries’ ideas across 
the peripheral countries, representing a form of 
Indirect Moral Imperialism. The paper proposes 
the establishment of regulatory and social con-
trol systems for clinical trials implemented in 
peripheral countries, through the formulation of 
ethical norms that reflect the specific contexts of 
these countries, along with the drawing up and 
validation of their own national norms.
Bioethics; Human Experimentation; Clinical 
Trial
Introduction
Bioethics has become an increasingly impor-
tant issue in the 21st Century. Through the recent 
adoption of the Universal Declaration on Bioeth-
ics and Human Rights, unanimously approved 
by the 191 countries present at the 33rd Section 
of the General Conference of the United Nations 
Educational, Scientific and Cultural Organiza-
tion (UNESCO), held in Paris in October 2005, 
bioethics has also widened its coverage:  in ad-
dition to the issues of biomedicine and biotech-
nology already considered to be within its remit, 
health, social and environmental issues have 
been added.
Scientific research, including clinical trials, 
has evolved from being an amateur activity in the 
18th Century, and a university practice in the 19th 
Century, to an industrial activity in the 20th Cen-
tury 1. The acceleration of the process of market 
globalization in recent years has made clinical 
trials more international and influenced their 
means of financing as well as the development of 
research practices 2.
The globalization of the world economy, 
rather than leading to a reduction in the gap be-
tween rich and poor across the world has further 
sharpened contradictions and reinforced exist-
ing problems. The majority of the populations 
in poor and developing (or peripheral) countries 
still struggle to guarantee the minimum condi-
tions necessary for their survival and dignity. In 
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Latin America, for example, the quality of public 
health services is generally low 3, and investments 
in the promotion of access to pharmacotherapies 
on the part of underprivileged populations are al-
most non-existent, meaning that individuals are 
responsible for almost 70% of all medical-related 
expenses in these countries 4. In addition, social 
security fails to cover approximately 40% of the 
populations, representing 218 million people 5.
However, people in the upper social strata of 
peripheral countries make up an important con-
sumer market of global goods and they are able 
to access sophisticated medical technologies.
Without the means to determine their re-
search priorities or to make substantial in-roads 
in the field of public health, peripheral countries 
often find themselves hostages to foreign financ-
ing. This assertion is supported by data from the 
Word Health Organization (WHO), according to 
which 87% of the US$ 2 trillion spent annually on 
health care across the globe benefits just 16% of 
the world’s population, while 10% of the global 
burden of disease is responsible for as much as 
90% of global expenditure on health research 6. It 
is common for research performed in developing 
countries to be guided exclusively by the logic 
of the market, with the aim of developing medi-
cines which may not be available in local public 
health systems in the future. In spite of criticisms 
of these kinds of clinical trials, many scholars, in-
cluding bioethicists in developed countries, have 
strived to justify these views 7,8,9.
In this context, one of the most important de-
bates has focused on placebo controlled trials. 
The Helsinki Declaration, the main international 
normative document on biomedical research, 
claims that the potential benefits and discomfort 
of a new diagnostic or therapeutic method should 
be compared to the benefits of current method(s) 
and prohibits the use of placebo groups if other 
effective methods already exist. However, this 
statement is now under strong pressure from a 
utilitarian rationale which places cost/benefit 
calculations and scientific arguments ahead of 
universal ethical concerns. Several authors, uni-
versities and national institutions, like the United 
States Food and Drug Administration, defend the 
morality of performing placebo controlled tri-
als when a methodological justification exists or 
when there are no medicines available to devel-
oping countries’ populations 10.
Therefore, it is no surprise to note that in re-
cent years, expressions such as “bioethics colo-
nialism” 11 and “moral imperialism” 12,13 started 
to appear in scientific magazines specialized in 
ethics and bioethics. During the final decades of 
the 20th Century – encouraged by certain theo-
retical currents in bioethics – ethics started to be 
used in many instances as a horizontal and “asep-
tic” tool, to the service of a neutral understanding 
and interpretation of the collective conflicts that 
occur within populations that have themselves 
been marginalized and socially excluded from 
their society’s development process.
Taking as a starting point an analysis of the 
expression “moral imperialism”, the objective of 
this study is to critically apply the term to multi-
centric clinical trials that have received foreign 
support and been performed in several periph-
eral countries in the Southern Hemisphere in re-
cent years.
Moral Imperialism
Moral Imperialism, applied to the field of bio-
ethics, is the aim of imposing, through different 
forms of coercion, moral standards from specific 
cultures, geopolitical regions and countries on 
other cultures, regions, or countries 14. The is-
sue of imperialism is a very broad one. In spite 
the fact that it is a relatively recent expression 
(in use since around 1870), a historical retro-
spective study would have to discuss categories 
such as: colonialism, neo-colonialism and un-
derdevelopment (as established by Marxist theo-
ries on imperialism); militarism and surplus, a 
new concept that substitutes more-worth (from 
monopolistic capitalism theory); market (social 
democratic theory); capitalism (liberal theory); 
anarchism, hegemony and State power (reason 
of State theory). As a general rule, in terms of 
political theory, imperialism means the violent 
expansion of a State to submit other territories to 
its influence or direct power and even to forms of 
economic exploitation, to the detriment of those 
subjugated States or peoples 15.
With regard to the issues of neocolonialism 
and underdevelopment – both of which are di-
rectly relevant to this discussion and specifically 
to the peripheral countries in the world – it is 
important to State that uncontrolled capitalism 
tends to maintain and strengthen unbalanced 
differences between rich and poor countries, 
which may only be overcome by the introduction 
of instruments that guarantee effective regional 
programming and concrete regional policies 
with worldwide dimensions. For the field of clini-
cal trials, the overall recommendation should be 
the same, an issue that will be addressed towards 
the end of this study.
Taking into account economic interests, par-
ticularly those of the pharmaceutical industries 
in developed countries, it is worth considering 
the problem of imposing TRIPS-Plus provisions 
(provisions that exceed the obligations under the 
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TRIPS Agreement) into Free Trade Agreements 
proposed by the United States of America to pe-
ripheral countries. These provisions can signifi-
cantly reduce the capacity of these countries to 
provide adequate access to medicines for their 
poorest citizens. Furthermore, strict intellectual 
property rules can jeopardize the development of 
production from the autonomous biomedical in-
dustry and erase the rights granted by the TRIPS 
Agreement under the World Trade Organization 
(WTO) 16.
Free Trade Agreements or FTAAs have been 
criticized by constituency groups in the USA and 
in peripheral countries and risk creating tensions 
and antagonisms between governments and civil 
society in these countries. Economic and political 
pressures for the acceptance of such provisions 
broaden the gap between both sides in terms 
of development and health protection which is 
clearly a sign of moral imperialism.
This text considers imperialism as an instru-
ment for the imposition of the cultural standards 
of one nation upon another, of a strong coun-
try upon more fragile ones 17. Among the fun-
damental principles of International Law, there 
are those related to the non-interference of one 
country into the internal affairs of another, and 
respect for the particular political and cultural 
norms of each country, with very specific excep-
tions. According to this line of thought and in 
recognition of the original meaning of the Latin 
word mores – meaning “way of being” or “way of 
proceeding”, habits of a people or a nation and 
upon which Roman Law was established – the 
moral plurality of different cultures should be 
respected. What is now happening is that some 
hegemonic cultures are using their economic 
clout and mass communication to manipulate 
and invade other cultures, especially in poor and 
developing countries, imposing their own unilat-
eral visions of the world. This moral imperialism 
transforms citizens into subjects; and the subject 
is a vassal, whose autonomy is very fragie or non-
existent and who is always under the control of 
someone stronger 17.
We can classify moral imperialism in the field 
of bioethics as being direct or indirect. An exam-
ple of Direct Moral Imperialism is the increasing 
pressure of some developed (or central) countries 
to impose their moral visions on others. A proof 
of this tendency is the recent actions (up to 2004) 
of the USA in imposing changes to the original 
content of the Helsinki Declaration on research 
involving human beings, with regard to the qua-
si-requirement of accepting as ethically correct 
the use of different methodological standards for 
different countries. That would mean the defini-
tive acceptance that  the methodological design 
for clinical trials (of new antiretroviral medicine, 
for example) should have one standard for poor 
countries and another for rich ones, tearing apart 
the theorem that held sway in the 20th Century, 
recognizing the equality of all  individuals 17. It 
also goes against Kant’s historical affirmation 
that human beings are an end in themselves. This 
distortion, defined by many scientists as “diver-
sity of ethical criteria” 18 has been labeled double 
standards that is, double standards in terms of 
the actions of researchers and double standards 
in the protection of research subjects, which is 
incompatible with the idea of human rights, and 
therefore, unacceptable by peripheral countries.
Indirect Moral Imperialism, in turn, is similar 
to active Moral Imperialism in the way that it is 
applied to peripheral countries but works in a 
different way. It is undertaken through prelimi-
nary educative actions aimed at convincing and 
co-opting people in more vulnerable countries, 
which in the medium- and long-term may be-
come members of ethics committees and gov-
ernment bodies that make decisions about the 
field of clinical trials.
Clinical multi-centric trials in peripheral 
countries and their implications
Direct Moral Imperialism
Some cases from recent world literature are con-
sidered here in order to contextualize the issue. At 
the end of 1997, Lurie & Wolf 19 issued an article 
denouncing 15 clinical trials designed to study 
the prevention of vertical transmission of HIV 
between pregnant women and their babies in so 
called developing countries, using a placebo for 
treating the control group 19. The chief editor of 
the magazine, in which the article was published 
– The New England Journal of Medicine (N Engl 
J Med) – wrote an editorial supporting the au-
thors’ position, and comparing these trials to the 
well known “Tuskegee case” 20. This analogy was 
made on the grounds that the HIV trials denied 
antiretroviral medicines to a group of women 
who participated in the research in the same way 
that the Tuskegee study denied penicillin to the 
subjects, even after the acknowledged proof of 
its efficacy. The criticism was based on the fact 
that these studies violated informed consent, ex-
ceeded the grounds of placebo use and took ad-
vantage of poor and misinformed populations.
Directors of the National Institutes of Health 
(NIH) and the Centers for Disease Control and 
Prevention (CDC), both American government 
agencies which financed the HIV research, im-
mediately defended the ethics of this trial, saying 
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that these situations were correct, and alleging 
that the scientific, social and economic complex-
ity of each trial should be considered 7. This issue 
has later highlighted on the pages of magazines 
and newspapers with broad circulations, such as 
the New York Times.
The most surprising aspect was that several 
researchers strongly defended the adoption of 
different ethical criteria for trials performed in 
developed countries and those undertaken in 
poor or developing countries. The argument was 
based on the relativity of each situation: “Ethi-
cal standards for trials involving human beings 
are universal, but not absolute: there are some 
principles that may be applied to all cases of tri-
als involving human beings, but their applica-
tion should also consider factors inherent to the 
particular situations (...) which vary according to 
the social and economic context, besides the trial 
scientific conditions” 8 (p. 288).
In other words, this argument contextual-
izes the issue by “putting it out of context”. The 
emerging question within the international 
academic community was then whether the 
adoption of different standards for trials and 
participants would be ethically justifiable. How-
ever, well-timed statements contested such ar-
guments, maintaining that they went entirely 
against the improvements achieved previously, 
in relation to universal political and civil rights 
21,22,23. Almost two years after this event, another 
trial on HIV performed in poor countries has giv-
en rise to similar inquiries. This research project 
was developed in rural areas of Uganda, with the 
aim of determining risk factors associated with 
the transmission of HIV (type 1) among hetero-
sexuals, trying to establish whether other sexu-
ally transmitted diseases could increase the risk 
of HIV infection 24 and to verify the relation be-
tween viral load and heterosexual transmission of 
HIV-1 25. For this trial, hundreds of people with 
HIV were observed for 30 months, but received 
no treatment and were provided with imprecise 
and incomplete information 26. The perplexity 
raised by this trial resulted from the fact that a 
project of this nature would never receive ap-
proval in the USA (the country that financed 
the research), or any other developed country, 
where patients with HIV or other sexually trans-
mitted diseases would receive prior informa-
tion and treatment. It was clear that different 
ethical standards had been adopted for Uganda. 
What is even more serious is that many trials 
developed in peripheral countries began to be 
limited to observing subjects and confirming 
avoidable harm as, for example, in the case of 
the HIV positive pregnant women who were 
treated with a placebo. In this case, the problem 
was aggravated by the fact that the studies had 
been approved by ethical revision committees, 
in both the country in which they were to be 
implemented and in the country that financed 
them, an issue that will be discussed later.
What is also surprising is the fact that some 
Editorial Boards of scientific publications – such 
as the N Engl J Med and The Lancet, traditional 
and prestigious international publications in 
the biomedical sciences – accepted to publish 
articles with the above mentioned distortions 
19,24,25. Regarding the N Engl J Med, the problem 
has been the subject of two editorials by Angell 
20,26, who was Chief Editor of the journal at the 
time, both of which are critical of the decision 
that was taken by the board and not approved 
by her. She admitted that she found herself in a 
minority but was nevertheless unsatisfied. Soon 
after this affair, she left (or was forced out of) the 
position that she had occupied for many years. 
The Lancet reviewed its position through an edi-
torial published in 2003 with the notable title of 
One Standard, Not Two 27. But as long as those 
issues raised in this present article are not con-
sidered within the context of the scientific pub-
lications themselves, including the decision to 
refuse publication under certain circumstanc-
es, these practices that are so negative towards 
more vulnerable members of society will remain 
in place.
Subsequent to the events mentioned above 
the USA, with support from many developed 
countries tried every means available to change 
the content of articles 19, 29 and 30 of the Helsinki 
Declaration, which refers to the double standards 
for research involving human beings including 
the obligation to continue to provide treatment 
to subjects after the research has ended. In spite 
of having obtained some favorable changes fol-
lowing their proposals to revise the 2002 CIOMS 
Guidelines at the World Health Assembly in To-
kyo in 2004 28, in the official discussion forum 
for changing the declaration, the USA’s inten-
tions were comprehensively buried by a major-
ity of representatives from other countries. The 
immediate reaction of the USA was to refuse to 
recognize officially the Helsinki Declaration as a 
reference tool for clinical trials involving human 
beings.
More recently, at the end of 2005, the Brazil-
ian Health Council was informed of the use of hu-
man subjects as research guinea pigs in the State 
of Amapá, near Brazil’s northern border with Ven-
ezuela. Public investigations showed that a group 
of people were each paid between US$ 6 and US$ 
10 a day to capture mosquitoes and to expose 
themselves to 100 bites from these mosquitoes 
that were infected by malaria at a rate of 3.5%. 
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The research was promoted by a North American 
University with cooperation from important Bra-
zilian research institutions and the support of the 
NIH. The blood feeding of captured mosquitoes 
on human beings was described in the protocol 
approved by the Institutional Review Board of 
the University (this protocol is available with the 
authors).
The capture of mosquitoes using the “human 
bait” method consists of exposure of parts of the 
body to attract the mosquitoes and capture them 
before they can bite. It is a routine method em-
ployed in research as well as for entomological 
surveillance. According to Forattini 29 the safety 
of the method depends on the ability of those 
responsible for capturing each mosquito before 
it can start to bite.
The procedure, when performed by skilled 
technicians or researchers, seems not to present 
higher risks than natural exposure, although no 
studies have ever corroborated this. The prob-
lem of this specific research was that members 
of the community itself were used to capture the 
mosquitoes; no criteria had been determined to 
select the individuals involved and their training 
began only a few weeks before capture started. 
Therefore, the level of safety involved in the pro-
cedures performed by the human subjects could 
never be compared to those performed by expe-
rienced technicians. Nonetheless, the expression 
guinea pigs is not appropriate when applied here, 
and the sensationalist exploitation by the press 
has hampered the approval of research initiatives 
that apply the procedure correctly.
The human feeding of mosquitoes captured 
in nature has not been described in other articles, 
although it has been used in previous studies 
30,31,32. Depending on the level of infection and 
the number of mosquitoes being fed, there are 
clearly significant risks involved in such a pro-
cedure, including hyper-infection, mixed infec-
tion, and other zoonotic diseases. Considering 
the risks involved, this procedure is totally differ-
ent from other forms of research such as plasmo-
dium inoculation for vaccine research, in which 
knowledge of the viral load and infection rates 
are far greater.
In the particular study under discussion 
here, it was established that individuals would 
allow themselves to be bitten by 100 mosqui-
toes, twice a year. There is no mention of the 
number of days during which this procedure 
would be undertaken. The researcher in charge 
of field activities admitted openly that the pe-
riod of exposure was planned to be four nights 
but that the procedure was performed only once 
and then cancelled. Notwithstanding, according 
to members of the riverside community where 
the research was conducted, exposure lasted for 
four nights at a time.
At two different stages in the original pro-
tocol, blood feeding by mosquitoes on human 
beings is mentioned clearly. The chapter that de-
scribes the methodology to be employed states 
that: “Mosquitoes captured from human landing 
counts will be blood-fed on team member volun-
teers who have taken the recommended Ministry 
of Health malaria prophylaxis for the region” (p. 
37) and in the description of the participation of 
the individuals, it states: “The team volunteers 
who blood feed the mosquitoes during the mark-
recapture experiments will be provided with the 
current Ministry of Health recommendation for 
chemoprophylaxis in this region” (p. 43). The doc-
ument of informed consent signed by research 
subjects also includes a clear description of the 
procedure in its item 6: “… you will be requested 
to feed 100 mosquitoes from your arm or leg for 
studies of marking-recapture. That will happen 
twice a year” (informed consent attached to the 
protocol; p. 2). It is clear that the reasoning used 
by the International Review Board to accept such 
a high degree of risk was based on double stan-
dards.
The public presentation by the Brazilian 
Health Council of the investigators’ report in April 
2006, showed that the blood feeding procedure 
and the capture of mosquitoes through exposure 
of members of the local communities were omit-
ted in the Portuguese translation of the protocol, 
and were also omitted in the consent document 
received by the National Commission on Ethics 
in Research (CONEP). As the English original ver-
sion cannot be examined without translation by 
a Brazilian Commission, the protocol was also 
approved in Brazil and the research began. The 
acknowledgement of these facts caused the im-
mediate suspension of the research by the Bra-
zilian Health Council and the publication of its 
results was forbidden.
Indirect Moral Imperialism
A paradigmatic text written by Emanuel & 
Grady 33 and published in January 2007, proposes 
a historical classification of four different phases 
relating to the development of clinical trials: (1) 
the “researcher paternalism” phase from 1940 to 
the beginning of the 1970s labeled “utilitarian-
ism”; (2) between the start of the 1970s and the 
mid-1980s, a phase known as “principalism”; 
(3) the “participant access” phase, between the 
mid-1980s and the mid-1990s, referring to basic 
individual rights and informed consent; and (4) 
the “community partnership” phase, from the 
mid-1990s to the present, represented by com-
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munitarian actions in the form of cooperation 
between institutions, people and countries.
This chronology is consistent with the line of 
action proposed by the NIH in relation to periph-
eral countries, starting with the USA’s rejection 
of the Helsinki Declaration in December 2004. 
The USA formally declared to the world that from 
that moment on, their researchers and the trials 
financed by their companies should follow their 
own guidelines, based on the ICH-GCP guide-
lines (International Conference on the Harmo-
nization – Good Clinical Practices). These guide-
lines reflect the tripartite agreement made in 
1997 between America, Japan and Europe, which 
are the world’s three leading medicine produc-
ers. As mentioned previously, the 2002 CIOMS 
version also includes changes that reflect these 
pressures.
More recently, USA changed its strategy to 
avoid international confrontation. It now pro-
motes frequent academic meetings in different 
countries with the support of the Fogarty Inter-
national Center, an institute of the NIH, with the 
aim of “instructing” researchers from peripheral 
countries in their particular way of interpreting 
the ethics of clinical trials, independently of the 
views of the governments of the countries from 
which these researchers hail 34. In Latin Amer-
ica, for example, many activities of this kind 
have been developed in Argentina, Chile and 
Venezuela over the last three years. The strategy 
implies that once these researchers have been 
appropriately “drilled”, they should start partici-
pating in Research Ethics Committees in their 
own countries, and in bodies that regulate such 
issues within their national governments. In this 
way, in just a few years, Emanuel & Grady’s 33 
paradigmatic proposal may become reality, 
since decisions related to ethics in clinical trials 
in different countries would be taken concretely 
and coherently by societies and communities. 
It thus represents a more subtle form of ethical 
imperialism. Tealdi 34 reports that in 10 years it 
would be possible to “instruct” 3,600 people in 
Latin America alone, changing some of the core 
references for ethics in clinical trials up to 2010, 
when the next revision of the Helsinki Declara-
tion is due. 
Regulation and control of trials in 
periphery countries
At this point in the text we present a proposal 
for the development of systems for the regula-
tion and social auditing of research in peripheral 
countries. These systems could be crucially im-
portant in guaranteeing significant changes in 
the current situation, and be to the benefit of vul-
nerable populations. This proposal has been pre-
sented to the Latin American and Caribbean Bio-
ethics Network of UNESCO (Redbioética) – and 
was also included in its first course on ethics in 
trials involving human beings in the program for 
distance learning and permanent education 2.
The development of a system for the regula-
tion and social auditing of research in poor and 
developing countries that is capable of promot-
ing cooperation in international research, and 
limiting moral imperialism and exploitation in 
international research would, in this proposal, 
involve reform along two main lines: (1) the 
drawing up of strict norms that are relevant to 
the socioeconomic and cultural contexts of these 
countries, involving the three axes of protection 
in research ethics (obtaining consent, minimiza-
tion of risks and maximization of benefits); (2) re-
form of the socio-political component, through 
the creation of normative regulatory instruments 
in the form of laws and ethical norms in research 
and the opening up of democratic spaces for 
social auditing, embodied in institutional or re-
gional committees and national commissions for 
clinical trials.
With regard to proposal 1 – the design of 
norms that are relevant to the socioeconomic 
and cultural contexts of peripheral countries 
– there are three components to be  considered: 
(a) improve the processes for obtaining informed 
consent, by giving less importance to the con-
tractual neo-liberal approach and more impor-
tance to a communitarian vision of autonomy 
for populations with low levels of education; (b) 
improve procedures aimed at minimizing risks 
to ensure equality for all subjects who participate 
in clinical trials; (c) improve procedures aimed at 
maximizing benefits, for this same reason.
In relation to proposal 2 – the creation and 
validation of national norms – there are also three 
components to be considered: (a) stimulate so-
ciopolitical participation in the production of 
documents through independent and inter-
disciplinary discussion forums, with the aim of 
obtaining a national consensus on ethical limits 
in research; (b) create national or institutional 
spaces for the evaluation of the ethical aspects 
of research protocols, with independent deci-
sion-making capacities and ethical overview of 
research; (c) build the capacities of members of 
ethics committees and commissions in the fol-
lowing areas:  knowledge development of ethical 
norms for trials and their interpretation, with rel-
evance to the local context; knowledge develop-
ment about the degree of risk of human partici-
pation depending on the main methodological 
techniques of research (here scientific issues can 
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be simplified in order to make them accessible to 
individuals who are not themselves researchers 
in the area of health); training on communica-
tion, developing arguments and on the critical 
analysis of certain arguments, to support deci-
sion-making processes.
Final considerations
The “partnership society” proposed by Emanuel 
& Grady 33 may come about as a result of actions 
by the USA which seek to promote the passive 
acceptance of research projects as a result of rich 
(central) countries’ interests in peripheral coun-
tries. In such a scenario, many of those who par-
ticipate in the decision-making process in poor 
and developing countries would receive the ap-
propriate “drilling” on the new/old ways of think-
ing, and assume that supposedly universal, but 
imperialist ethics are in fact appropriate ethics 
for their populations. This could be considered to 
be an example of the ideology of double standards 
or the persuasion of researchers through special 
methods of “instruction” on research ethics.
Nonetheless, it is important to highlight the 
resistance of some countries in the Southern 
Hemisphere to attempts to import bioethical 
colonialism and to acknowledge the benefits of 
ethical imperialism. Redbioética, a network cre-
ated with the support of the Regional UNESCO 
Bureau in Mexico,  is proof of such resistance 
and is critical of importing “ethical packages” 
into different contexts and cultures.
Redbioética is fully open to bilateral ex-
changes with other institutions, countries and 
regions of the world, aimed at sharing experi-
ence and best practice. In recent years, some 
Latin American countries have provided con-
crete responses to ethical invasions, through 
improving legislation and academic programs 
for clinical researchers and bioethicists, which 
are more critical and concerned with the socio-
politic feedback of their trials, thus creating a 
new culture of public participation, citizenship 
and social responsibility.
Resumo
Imperialismo moral é a intenção de impor padrões 
morais de determinadas culturas, regiões geopolí-
ticas e países a outras culturas, regiões ou países. O 
Imperialismo Moral Direto pode ser exemplificado 
com diversos episódios recorrentes de ensaios clínicos 
multicêntricos promovidos por países desenvolvidos 
(centrais) em países pobres e em desenvolvimento (pe-
riféricos), especialmente projetos relacionados com a 
teoria do “double standard” de pesquisas. Com a recu-
sa da Assembléia Geral da Associação Médica Mundial 
em alterar a Declaração de Helsinki, que significaria 
o reconhecimento moral da referida teoria, os Estados 
Unidos abandonaram a declaração, passando a pro-
mover seminários regionais em países periféricos com 
objetivo de “treinar” investigadores nas visões éticas 
dos interesses estadunidenses. Estes passam a ser du-
plicadores das idéias centrais, em diferentes instâncias 
das nações periféricas, caracterizando uma forma de 
Imperialismo Moral Indireto. O estudo propõe a cons-
trução de sistemas de regulação e de controle social 
para os ensaios clínicos a serem implementados nos 
países periféricos, por meio da formulação de normas 
éticas adequadas às características contextuais destes 
países, conjuntamente com a criação e validação de 
documentos normativos nacionais próprios.
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